Skip to main content

TRV GP IV, LLC

13F filer · CIK 0001688325
Reported Aug 10, 2026
13F portfolio value$254MU.S. long equity reported on 13F
Positions20 new · 0 closed
Net flow last quarter$0Buys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 10, 20262 positions
MAZEMaze Therapeutics, Inc.$134M52.63%8.06%Not reportedQ1 2025
TNGXTango Therapeutics, Inc.$120M47.37%3.79%Not reportedQ3 2021
Q1 2026Reported May 7, 20262 positions
MAZEMaze Therapeutics, Inc.$134M50.04%9.00%Not reportedQ1 2025
TNGXTango Therapeutics, Inc.$133M49.96%4.42%-19.1%Q3 2021
Q4 2025Reported Feb 13, 20262 positions
MAZEMaze Therapeutics, Inc.$185M72.65%9.07%-26.3%Q1 2025
TNGXTango Therapeutics, Inc.$69.8M27.35%5.79%-43.2%Q3 2021
Q3 2025Reported Nov 13, 20252 positions
MAZEMaze Therapeutics, Inc.$157M57.49%12.63%Not reportedQ1 2025
TNGXTango Therapeutics, Inc.$116M42.51%12.43%-17.8%Q3 2021
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.